MOTS-CvsThymalin

MOTS-C (Mitochondrial Open Reading Frame of the Twelve S rRNA type-C) is a 16-amino-acid peptide encoded in the mitochondrial genome within the 12S rRNA gene. Its discovery in 2015 by Dr. Changhan David Lee at USC was groundbreaking because it demonstrated that the mitochondrial genome encodes functional peptides beyond the 13 oxidative phosphorylation subunits traditionally recognized — establishing mitochondria as endocrine organelles capable of producing signaling hormones.

MOTS-C's primary metabolic mechanism centers on activation of AMP-activated protein kinase (AMPK), the cell's master energy sensor. MOTS-C activates AMPK by increasing the AMP/ATP ratio through inhibition of the folate cycle and de novo purine biosynthesis pathway. Specifically, MOTS-C inhibits the folate/methionine cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase), leading to accumulation of the intermediate AICAR — which is itself an endogenous AMPK activator. This creates a feed-forward AMPK activation signal.

Activated AMPK triggers a cascade of metabolic adaptations that mimic exercise: increased glucose uptake via GLUT4 translocation (independent of insulin signaling), enhanced fatty acid oxidation through ACC phosphorylation and CPT-1 activation, stimulation of mitochondrial biogenesis via PGC-1α, and suppression of mTORC1-mediated protein synthesis to conserve energy. Under metabolic stress, MOTS-C translocates from the cytoplasm to the nucleus — a remarkable feat for a mitochondria-encoded peptide — where it directly regulates nuclear gene expression by interacting with antioxidant response elements (AREs) and NF-κB target genes. This nuclear translocation represents a novel mechanism of mitonuclear communication — the mitochondria literally sending a peptide messenger to the nucleus to coordinate the cellular stress response. MOTS-C levels decline with age in humans, correlating with the age-related decline in metabolic fitness, insulin sensitivity, and exercise capacity, making it a compelling target for metabolic aging intervention.

Thymalin is a complex of short peptides extracted from bovine thymus glands, representing the biologically active fraction of thymic hormones. The thymus gland is the primary organ of T-cell maturation — bone marrow-derived T-cell precursors migrate to the thymus where they undergo positive and negative selection, emerging as mature, immunocompetent CD4+ helper and CD8+ cytotoxic T cells. The thymus produces a suite of peptide hormones that guide this maturation process, and Thymalin contains a mixture of these bioactive peptides.

The peptide complex acts at multiple points in the immune system. It promotes the differentiation of pre-T cells into mature T-cell subsets, restoring the CD4/CD8 ratio toward normal values (typically 1.5-2.5:1 in healthy individuals). It enhances natural killer (NK) cell cytotoxic activity, which is critical for immune surveillance against virus-infected and neoplastic cells. It modulates cytokine production — generally promoting a balanced Th1/Th2 response rather than driving either extreme — and enhances macrophage phagocytic capacity.

The relevance to aging is direct: the thymus undergoes progressive involution (shrinkage) beginning at puberty, and by age 60-70, most thymic tissue has been replaced by fat, with minimal residual T-cell educating capacity. This thymic involution is a major driver of immunosenescence — the age-related decline in immune function that increases susceptibility to infections, cancers, and autoimmune conditions while reducing vaccine responsiveness. Thymalin aims to pharmacologically replace the thymic peptide signals lost through involution, partially restoring the immune system's ability to produce new, functional T cells. Research from the Khavinson group has reported that Thymalin treatment in elderly patients was associated with reduced mortality and improved immune markers over long-term follow-up, though these studies require independent replication in Western clinical settings.